Manufacturing Quality Control & Non-Conformance Technician

FUJIFILM Americas welcomes Michael J. Hartman as Vice President, General Counsel and Secretary. VALHALLA, N.Y., August 27, 2026 - FUJIFILM Holdings America Corporation (FUJIFILM Americas) today announced the leadership appointment of Michael (Mike) J. Hartman as Vice President, General Counsel and Secretary, effective August 24. This new appointment strengthens the leadership team for FUJIFILM Americas regional headquarters, which represents more than 20 subsidiaries across the United States, Canada, Brazil, and Colombia. "We are very pleased to welcome Mike to Fujifilm's executive leadership team," said Kenya Nakashima, President, FUJIFILM Holdings America Corporation. "With 20-plus years of leading legal functions and teams for global healthcare and technology industry companies, Mike's depth of experience is impressive and will help guide the continued success of Fujifilm's broad and diverse businesses, as well as support our future expansion through both organic growth and acquisition." Most recently, Hartman served as Senior Vice President & General Counsel, Americas for Elekta, a global leader in radiation therapy and oncology software. Prior to that, he was Lead Division Attorney for the U.S. Industry Automation Division at Siemens. Earlier in his career, Hartman served as General Counsel & Chief Compliance Officer for Employease, a SaaS HRIS provider acquired by ADP. "Fujifilm's long history in imaging and its success in growing its leadership in the healthcare and technology sectors were key parts of what drew me to this role," said Hartman. "Fujifilm is a major player not only in the healthcare and life sciences fields, but in the electronic materials and business innovation industries as well. The company's diversification story is truly inspiring, and I look forward to playing a role in enabling its continued growth and transformation." Hartman received his Juris Doctor from the University of Georgia School of Law and his bachelor's degree from Virginia Tech. About Fujifilm. FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale and service of Fujifilm products and services. The company's portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography. For more information, please visit: https://www.fujifilm.com/FUJIFILM Corporation/en/about/region. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by its Group Purpose of "giving our world more smiles," FUJIFILM Corporation address social challenges and create a positive impact on society through its products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, FUJIFILM Corporation aspire to continue its evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: https://holdings.fujifilm.com/en/. Media contact.

$1.26M funding moves UOW cancer imaging research closer to clinical trials. * Education * 25 Aug 2026 1:09 pm AEST * Share World-first quantum photon imaging technology could help doctors see tumours more clearly during treatment A promising cancer imaging technology developed by researchers from the University of Wollongong's (UOW) Centre for Medical Radiation Physics (CMRP) has moved a step closer to clinical trials after securing $1.26 million in funding through the Australian Government's Critical Technologies Challenge Program and signing a partnership with global radiotherapy manufacturer Elekta. The project builds on earlier research demonstrating the feasibility of Lantern, a new imaging system that uses quantum photon-counting detectors to dramatically improve the clarity of images used during radiotherapy treatment. The funding will support the next phase of development, led by Associate Professor Saree Alnaghy, Professor Susanna Guatelli and Dr Matthew Newall, in partnership with clinicians at the Nelune Comprehensive Cancer Centre (NCCC) at Prince of Wales Hospital and Elekta. Dr Alnaghy said these partnerships have enabled rare access to a dedicated research linear accelerator (linac) radiotherapy machine in Australia, reducing the time to patient trials. Discover more "Having a dedicated research linac means we can rapidly test and modify the technology in ways that just aren't possible on machines that are also used for patient treatment," Dr Alnaghy said. "This is the first technology of its kind on a linac, and that puts us about four or five years ahead of other research groups and closer to real-world clinical testing." Government Radiotherapy relies on imaging to locate tumours before treatment, but current systems can have limitations in clearly distinguishing some soft-tissue structures in certain clinical contexts. Lantern is being developed to overcome this by using photon-counting technology to measure the energy of each X-ray passing through the body, providing far more anatomical detail. "Because our detector is more efficient, we can deliver less imaging dose and avoid additional radiation, which is particularly beneficial for paediatric patients" Dr Alnaghy explained. "This will also be valuable for cancers that are harder to visualise, like pancreatic, liver and prostate tumours, and small metastatic tumours in the brain." Head of External Research at Elekta, Wayne Lomax, said the company's partnership with UOW will help bridge the gap between promising research and technologies being used in clinical practice. "As radiotherapy moves toward highly personalised and adaptive treatment, innovations like this have the potential to significantly enhance precision and support the next generation of techniques," he said. Director of Radiation Oncology at NCCC and UOW Honorary Professorial Fellow, Dr Michael Jackson, said the hospital's role in providing space to commence trials will help the research move towards routine patient care. "A crucial benefit of this technology is that designed to work and fit onto existing, standard radiotherapy linacs so hospitals won't have to buy a whole new machine," Dr Jackson said. "In time, it will be used by many centres and potentially provide an additional imaging approach for radiotherapy centres." "Within the next few years, this is going to make a huge impact on practical cancer treatment." Discover more Business Operations Courts & Judiciary

HealthCare Global Enterprises has begun treating cancer patients with Karnataka's first Elekta Unity MR-Linac at its Bengaluru facility. The system combines a 1.5 Tesla MRI scanner with a linear accelerator, enabling real-time tumour visualisation and treatment adaptation during radiation therapy. The technology allows clinicians to adjust treatment plans based on anatomical changes between sessions, delivering precise radiation while protecting healthy tissue. This is particularly valuable for tumours near critical organs or in areas where anatomy changes during treatment. One of the first patients, a 74-year-old man with prostate cancer, completed a five-week treatment course without interruption. The Global Cancer Observatory estimates India's cancer cases will reach 2.08 million by 2040, a 57.5% increase from 2020 levels, making such precision technology increasingly important.